Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics

Qiang Niu,Yu Liu,Yujing Zheng,Ziwei Tang,Yuna Qian,Ruogu Qi,Jianliang Shen,Ping Zhao
DOI: https://doi.org/10.1016/j.apsb.2022.11.002
IF: 14.903
2022-11-06
Acta Pharmaceutica Sinica B
Abstract:Pyroptosis provides a new window for relieving the tumor immunosuppressive microenvironment (TIM) and promoting systemic immune responses for tumor treatments. However, gasdermin D (GSDMD), a key protein in the pyroptosis process mediated by caspase-1, is low expressed in the majority of tumor cells and small-molecule inhibitors of DNA methylation suffer from nonspecific or single-function defects. To address these issues, hexahistidine (His 6 )-metal assembly (HmA) was employed as the drug delivery vector to load nigericin (Nig) and decitabine (DAC) affording a dual-drug delivery system (Nig+DAC)@HmA. The (Nig+DAC)@HmA nanoparticles are efficiently internalized by cells through endocytosis, easily escape from the lysosome, and are highly distributed in the tumor sites. DAC up-regulates the expression of GSDMD which is then cleaved by the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome and caspase-1 protein activated by Nig. Effective cancer cell pyroptosis is thus achieved and induces a significant systemic antitumor immunity for impressive tumor suppression with negligible side effects in vivo . Our results suggest that such an easy-to-manipulate self-assembled nano-system (Nig+DAC)@HmA provides a new anticancer path by enhancing pyroptosis through reinforced inflammation.
pharmacology & pharmacy
What problem does this paper attempt to address?